ADA Releases Updates to 2019 Standards of Care for Diabetes

The American Diabetes Association has updated its 2019 standards of care for diabetes focusing on the improvement of cardiovascular and renal health in individuals with diabetes.

The updates come following the recent publishing of research that “indicated an urgent need to update” the 2019 Standards of Care.

The update includes:

• Icosapent ethyl can be considered in patients with diabetes and atherosclerotic cardiovascular disease or other cardiac risk factors who are taking a statin and who have controlled LDL cholesterol but have elevated triglycerides.
• Several sections have been revised to include information on dapagliflozin, which has been shown to reduce hospitalization for heart failure and the progression of chronic kidney disease (CKD).
• In patients with diabetes and CKD, the approved use of dapagliflozin per estimated glomerular filtration rate has been revised from ≥60 mL/min/1.73 m2 to ≥45 mL/min/1.73 m2.

"These Living Standards of Care updates via the online annotations to our yearly Standards of Care enable us to translate and communicate significant research findings that will empower health professionals to provide optimal care for millions of Americans living with diabetes,” said William T Cefalu, MD, the ADA’s Chief Scientific, Medical and Mission Officer.

—Michael Potts

Reference:

American Diabetes Association® issues critical updates to the 2019 standards of medical care in diabetes [press release]. Arlington, Virginia. March 27, 2019.https://www.diabetes.org/newsroom/press-releases/2019/ada-issues-critical-updates-to-2019-standards-of-care.html.